Evaluation of the Safety and Performance of SYMATESE AESTHETICS ESTYME® MATRIX Round Microtextured Silicone Gel-Filled Breast Implants in the Breast Augmentation (EMMA)

  • End date
    Aug 28, 2024
  • participants needed
  • sponsor
    Symatese Aesthetics
Updated on 28 April 2022
Accepts healthy volunteers


The purpose of this study is to collect clinical data to evaluate the safety and performance of ESTYME® MATRIX Round microtextured breast implants in patients who receive these silicone gel-filled implants as part of their breast augmentation surgery in primary intention. This study also aims to measure patient and surgeon satisfaction.

An initial study of all ESTYME® MATRIX implants was conducted between 2018 and 2021. The purpose of the current EMMA study is to complete the data from this first study on a larger number of implants, and only on the ESTYME® MATRIX Round Microtextured Silicone Gel-Filled Breast Implants range for primary intention breast augmentation, with a view to obtaining marketing authorization (CE marking).

Condition Bilateral Breast Augmentation
Treatment ESTYME® MATRIX Round Microtextured Silicone Gel-Filled Breast Implants
Clinical Study IdentifierNCT05336526
SponsorSymatese Aesthetics
Last Modified on28 April 2022


Yes No Not Sure

Inclusion Criteria

Aged between 18 and 65 years
Eligible for bilateral breast augmentation in primary intention
general breast enlargement for cosmetic purposes
surgical correction of various congenital or acquired anomalies such as amastia, aplasia, hypomastia, hypoplasia, asymmetries _, Poland's syndrome_ , ptosis … correction of asymmetries and Poland's Syndrome with concomitant augmentation of the second breast (bilateral implantation)
Signature of Patient Information Consent (PIC) & willingness to comply with the
protocol assessments and follow up visits
Affiliation to the social security regime

Exclusion Criteria

Local or systemic infection or abscess anywhere in the body
Existing carcinoma or pre-carcinoma of the breast with or without treatment
History of subcutaneous mastectomy
Subject with previous tissue expansion
Diagnosis of active cancer of any type
Pregnant subject or intending to become pregnant within three (3) months after the implant procedure (women of childbearing potential must use effective contraception from 1 month before the implantation procedure until 3 months after the implantation procedure)
Has breastfed within three (3) months the implant surgery, or is still breastfeeding
Tissue characteristics determined as clinically inadequate or unsuitable by the surgeon (i.e. tissue damage resulting from radiation, inadequate tissue or compromised vascularity, known wound healing complications)
Has been previously implanted with a silicone implant or history of failure following cosmetic augmentation
History of autoimmune disease such as, but not limited to, lupus and scleroderma
Any condition or treatment for any condition which, in the opinion of the investigator, may constitute an unwarranted surgical risk (e.g. severe lung or cardiac disease, unstable medical conditions, anaesthesia allergy, heavy smokers…)
Anatomic or physiologic abnormality which could result to significant post-operative complications
History of sensitivity to foreign materials or known allergy to any component of the ESTYME® MATRIX Round Microtextured Silicone Gel-Filled Breast Implant
Known alcohol abuse or history of alcohol abuse
Psychological instability
Underlying disease (HIV-positive, heart failure, renal insufficiency, diabetes, hypertension)
Implanted metal or metal devices, history of claustrophobia, or other condition that would make a magnetic resonance imaging (MRI) scan prohibitive
Unwilling to undergo any further surgery for revision
Unrealistic/unreasonable expectations that entail a risk for the surgical procedure
Participating in another clinical study or within exclusion period of a previous clinical study as determined by the investigator
Has sociological, cultural or geographical factors which could interfere with evaluation or completion of the study
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact


Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note